IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA Places Import Alert on Products from Two Ranbaxy Plants

10:27 AM MDT | September 18, 2008 |

Alex Scott

U.S. FDA says it has issued an import alert for officials to detain drugs reaching the U.S. border that have been made at two Indian plants owned by pharmaceutical manufacturer Ranbaxy Laboratories (Gurgaon, India). FDA says it has issued two warning letters to Ranbaxy relating to the company’s generic pharmaceutical production plants at Dewas and Paonta Sahib, India for deviating from U.S. good manufacturing practice (GMP) .  FDA says it has taken the severe action to detain product made at the plants “because of the extent and...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa